| Date Filed | Type | Description |
| 06/07/2022 |
4
| Matthews Christine (CFO) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Sold 82 shares
@ $0.71, valued at
$58.2 |
|
| 06/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/01/2022 |
4
| Matthews Christine (CFO) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Sold 8,116 shares
@ $0.2101, valued at
$1.7k
|
|
| 04/01/2022 |
4
| KELLERMAN DONALD J (VP, Clinical Dev & Med Affairs) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Sold 4,006 shares
@ $0.2101, valued at
$841.7 |
|
| 04/01/2022 |
4
| Lo Steven (CEO) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Sold 23,633 shares
@ $0.2101, valued at
$5k
|
|
| 12/09/2021 |
4
| Yang Elaine (Director) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Granted 90,000 options to buy
@ $0.558, valued at
$50.2k
|
|
| 12/09/2021 |
3
| Yang Elaine (Director) has filed a Form 3 on Zosano Pharma Corp |
| 11/24/2021 |
4
| GREATHOUSE KENNETH (Director) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Sold 10,000 shares
@ $0.6018, valued at
$6k
|
|
| 10/19/2021 |
4
| KELLERMAN DONALD J (VP, Clinical Dev & Med Affairs) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Granted 10,000 shares
@ $0
Granted 20,000 options to buy
@ $0.6342, valued at
$12.7k
|
|
| 10/19/2021 |
4
| Matthews Christine (CFO) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Granted 56,250 shares
@ $0
Granted 112,500 options to buy
@ $0.6342, valued at
$71.3k
|
|
| 10/19/2021 |
4
| Lo Steven (CEO) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Granted 118,750 shares
@ $0
Granted 237,500 options to buy
@ $0.6342, valued at
$150.6k
|
|
| 06/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/14/2021 |
4
| GREATHOUSE KENNETH (Director) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Granted 15,000 shares
@ $0
Granted 30,000 options to buy
@ $0.9318, valued at
$28k
|
|
| 06/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2021 |
4
| Lewis Hayley (See Remarks) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Sold 1,709 shares
@ $0.805, valued at
$1.4k
|
|
| 06/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/25/2021 |
4
| McGee Kathy M. (Director) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Granted 90,000 options to buy
@ $0.73, valued at
$65.7k
|
|
| 05/25/2021 |
3
| McGee Kathy M. (Director) has filed a Form 3 on Zosano Pharma Corp |
| 05/18/2021 |
4
| GREATHOUSE KENNETH (Director) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Granted 21,000 shares
@ $0.7291, valued at
$15.3k
|
|
| 04/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/01/2021 |
4
| Lewis Hayley (See Remarks) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Granted 32,500 shares
@ $0
Granted 65,000 options to buy
@ $1.2, valued at
$78k
|
|
| 04/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/19/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2020 |
4
| GREATHOUSE KENNETH (Director) has filed a Form 4 on Zosano Pharma Corp|
Txns:
| Granted 7,500 shares
@ $0 |
|
| 06/29/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|